Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Robots and dyes could spare testicular cancer patients unnecessary treatment

NCT ID NCT06133543

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times

Summary

This study tests a new, robot-assisted technique to see if testicular cancer has spread to nearby lymph nodes. Doctors inject a green dye into the testicle, then use a robot with a special camera to find and remove the first lymph node that drains the tumor. The goal is to improve accuracy and reduce overtreatment. The trial will enroll 44 adults with early-stage testicular cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital of Duesseldorf

    RECRUITING

    Düsseldorf, Germany

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

indocyanine green (ICG) dye

What this could lead to

If successful, this could replace standard staging with a more precise, minimally invasive procedure, reducing unnecessary treatments and side effects.

What could go wrong

This is a small, early feasibility study (44 participants) with no control group. The technique may not achieve the desired 90% sensitivity or may have complications like retrograde ejaculation.

Conditions

The condition(s) this trial relates to.

Neoplasms, Germ Cell and Embryonal nongerminomatous germ cell tumor Nonseminomatous germ cell tumor seminoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.